EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease

Xu Liu, Xuanjing Liu, Yuning Liu, Bo Yang, Yangdanyu Li, Fujia Li, Kun Qian, Xuesong Liu, Lishun Xiao, Guiyun Cui, Chuanying Xu iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Xu Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Ceramides, Parkinson Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science and Technology Innovation Project of Xuzhou Health Commission, National Natural Science Foundation of China, Leadership program through open competition in Xuzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Prior research has underscored the importance of sphingolipid metabolism in Parkinson's disease (PD) pathogenesis. Our objective was to explore the associations between plasma ceramide levels and PD patients with cognitive dysfunction (PD‐CD).

Methods

We enrolled two study populations from Eastern China and the Parkinson's Progression Markers Initiative (PPMI), comprising 290 (100 HCs, 160 PDs, and 30 MSAs) and 429 (125 HCs and 304 PDs) participants, respectively. The plasma levels of ceramides (Cer 16:0, Cer 18:0, Cer 24:0, and Cer 24:1) were tested via HPLC–MS/MS analysis.

Results

Compared with those in the HC group, the plasma levels of Cer 18:0, Cer 24:1, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were higher in both the PD and MSA groups. Significant differences in the plasma levels of Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were observed among the PD‐NC (PD with normal cognition), PD‐MCI (PD with mild cognitive impairment), and PDD (PD dementia) groups, with the PDD group exhibiting the highest levels. PD patients with higher baseline levels of plasma ceramides (specifically, Cer 18:0, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0) demonstrated accelerated cognitive decline compared with individuals who had lower baseline plasma ceramide levels during the 5‐year follow‐up period. A biomarker panel including Cer 18:0/Cer 24:0 and Cer 24:1/Cer 24:0 could effectively differentiate PD‐CD from PD‐NC with notable diagnostic accuracy.

Conclusions

Our results indicate that plasma ceramide levels could potentially be used as diagnostic biomarkers for PD‐CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeramidesParkinson DiseaseCognitive DysfunctionHumansFemaleMaleMiddle AgedAgedBiomarkers

Stichwörter der Autor:innen

Parkinson's diseasebiomarkerceramidecognitive dysfunction

Substanzen

CeramidesBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Neurology, the First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu, China.

ORCID-Profile: Chuanying Xu

Förderung

  • Medical Science and Technology Innovation Project of Xuzhou Health Commission
  • National Natural Science Foundation of China
  • Leadership program through open competition in Xuzhou Medical University
  • Jiangsu Postgraduate Research and Practice Innovation Program
  • The National Natural Science Foundation of China
  • The China Postdoctoral Science Foundation

Zitieren

APA

Liu, X., Liu, X., Liu, Y., Yang, B., Li, Y., Li, F., Qian, K., Liu, X., Xiao, L., Cui, G., & Xu, C. (2024). Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70082

Vancouver

Liu X, Liu X, Liu Y, Yang B, Li Y, Li F, et al. Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70082

BibTeX
@article{Liu2024,
  author = {Liu, Xu and Liu, Xuanjing and Liu, Yuning and Yang, Bo and Li, Yangdanyu and Li, Fujia and Qian, Kun and Liu, Xuesong and Xiao, Lishun and Cui, Guiyun and Xu, Chuanying},
  title = {Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.70082}
}
Kostenlos starten →